Anti-CCL2: building a reservoir or opening the floodgates to metastasis?

Breast Cancer Res. 2015 May 21;17(1):68. doi: 10.1186/s13058-015-0573-4.

Abstract

Neutralisation of macrophage chemoattractant C-C chemokine ligand 2 (CCL2) has shown reduced metastasis and enhanced survival in numerous experimental models of tumorigenesis. However, important new findings reported in Nature by Momo Bentires-Alj's laboratory demonstrate that withdrawal of anti-CCL2 treatment accelerates lung metastasis and death in mice. The study highlights the need to consider longer term consequences of therapeutic intervention of metastatic disease, especially with regard to transient interference with the tumour microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Chemokine CCL2 / antagonists & inhibitors*
  • Chemokine CCL2 / metabolism*
  • Female
  • Neoplasm Metastasis*
  • Neovascularization, Pathologic*

Substances

  • Chemokine CCL2